Biomarkers for Prostate Cancer: Whom to Treat

Posted by Gerald L. Andriole, Jr., MD | Jun 2018

Gerald L. Andriole, Jr., MD, presented “Biomarkers for Prostate Cancer: Whom to Treat” during the Jackson Hole Seminars on February 7, 2018 in Jackson Hole, Wyoming.

How to cite: Andriole, Gerald. “Biomarkers for Prostate Cancer: Whom to Treat” February 7, 2018. Accessed Apr 2024. https://dev.grandroundsinurology.com/biomarkers-for-prostate-cancer-whom-to-treat/

Biomarkers for Prostate Cancer: Whom to Treat

Summary:

Gerald L. Andriole, Jr., MD, discusses prostate cancer risk stratification and life expectancy prediction according to National Comprehensive Cancer Network (NCCN) guidelines. Furthermore, he discusses the efficacy of genetic tests such as Decipher, Oncotype Prolaris, and Promark.

About The Author

Gerald L. Andriole, Jr., MD

Gerald L. Andriole, Jr., MD, is the Robert K. Royce Distinguished Professor and Chief of Urologic Surgery at Barnes-Jewish Hospital, the Siteman Cancer Center, and Washington University School of Medicine in St. Louis, Missouri. Dr. Andriole received his medical degree from Jefferson Medical College in Philadelphia, Pennsylvania. He trained in surgery at Strong Memorial Hospital and the University of Rochester and completed his Urology Residency at Brigham and Women’s Hospital and Harvard Medical School. Subsequently, he was a Fellow in Urologic Oncology at the National Cancer Institute in Bethesda, Maryland. Dr. Andriole has over 35 years of consistent contributions in the areas of BPH and prostate cancer screening and prevention research. He has contributed well over 400 peer-reviewed publications and serves on the editorial boards of several prestigious journals. He is Chairman of the Prostate Committee of the National Cancer Institute’s Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, and PI of the NIDDK Multidisciplinary Approach to Urologic Pelvic Pain (MAPP) and Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN). He was Chairman of the Steering Committee of the REDUCE Prostate Cancer Prevention Trial, as well as PI of both the NIDDK Medical Therapy of Prostatic Symptoms (MTOPS) BPH trial and the NIDDK Complementary and Alternative Medicine for Urinary Symptoms (CAMUS) study. He is a member of the American Urological Association, the American Association for Cancer Research, the American Society of Clinical Oncology, the American Surgical Association, the American Association of Genitourinary Surgeons, and the Clinical Society of Genitourinary Surgeons, among other societies.

Join the GRU Community

- Why Join? -

CARDEN JENNINGS PUBLISHING CO., LTD.

Your GRU

– Account Dashboard
– Your Courses

Recent Updates

PDF Embedder Test Jan 2022
Genetic Testing and Prostate Cancer – Welcome Jan 2022
Current Status of PSMA Diagnostics Aug 2021
Genetic Testing and Prostate Cancer Aug 2021
What’s New in Active Surveillance for Prostate Cancer in 2021 Aug 2021

Exercise & Wellness

Share This